Comparative Pharmacology
Head-to-head clinical analysis: MEPROSPAN versus TRANMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROSPAN versus TRANMEP.
MEPROSPAN vs TRANMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
Tianeptine is a selective serotonin reuptake enhancer (SSRE) and also modulates glutamatergic signaling via AMPA and NMDA receptors. It increases serotonin transport in presynaptic neurons and enhances neuroplasticity.
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
50 mg orally every 8 hours, may increase to 100 mg every 8 hours if needed.
None Documented
None Documented
Terminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
4-6 hours in adults; prolonged in hepatic impairment (up to 12 hours) and elderly.
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Renal: ~60% as unchanged drug, biliary/fecal: ~30% as metabolites, remainder as unchanged drug.
Category C
Category C
Anxiolytic
Anxiolytic